Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

PMV Pharma Reports $34.4 Million Third-Quarter Net Loss

None

PMV Pharmaceuticals (PMVP) reported a net loss of $34.4 million, or $0.52 per basic and diluted share, for the third quarter ended September 30, 2026. The company reported $108.5 million in cash, cash equivalents and marketable securities at quarter-end.

PMV Pharma said it completed an oversubscribed $50 million public offering and plans to submit a rezatapopt NDA for platinum-resistant or refractory ovarian cancer in the first quarter of 2027.

  • Research and development expense was $16.1 million, down from $18.2 million a year earlier.
  • General and administrative expense was $4.0 million, compared with $4.3 million in the prior-year quarter.
  • Net cash used in operations was $52.4 million for the nine months ended September 30, 2026.
  • The company expects its cash runway to extend into the first quarter of 2028.
  • Updated Phase 2 PYNNACLE data are scheduled for a late-breaking oral presentation at ENA 2026.

$PMVP Hedge Fund Activity

We have seen 17 institutional investors add shares of $PMVP stock to their portfolio, and 32 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles